ERIS Lifesciences Ltd (ERIS) is currently trading at 1,323.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Eris Lifesciences is an Indian branded formulations company focused on chronic and specialist therapies with expanding sterile injectables and biologics capabilities; it develops, manufactures and commercializes products across cardiology, diabetes, dermatology and other specialty areas and now owns EU‑GMP capable biologics and sterile injectable assets after multiple strategic acquisitions. The Domestic Branded Formulations (DBF) segment delivered steady growth (Q3 DBF revenue Rs.696 crore, +10% YoY) with strong profitability (Q3 DBF EBITDA margin ~36.5% and 9M margin ~37.1%), and management expects FY26 DBF growth of ~12% and Q4 to reflect the full benefit of recent price increases. Eris has materially improved insulin market positions since the Biocon acquisition: RHI cartridge share tripled (10% Apr‑24 to 28% Dec‑25) and overall RHI+Glargine share rose from 9% to 16%, underpinning a stated objective of 25% market share and in‑house insulin manufacturing ramp at Bhopal. International business is transitioning to a CDMO‑led growth engine, reporting Q3 revenue Rs.111 crore (+45% YoY) and providing FY27 international visibility of Rs.550–600 crore revenue with EBITDA Rs.180–200 crore, reflecting confirmed contracts, CDMO investments, and planned export scale from AMD and Biologics sites. Balance sheet and capital allocation: net debt reduced materially from ~4x to ~2x Net Debt/TTM EBITDA, with a targeted <1.5x by Dec‑26 while maintaining Rs.750–800 crore capex guidance for FY26–FY28 to support injectables, insulin/GLP‑1 and CDMO expansion.

Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,237.90 and a high of ₹1,737.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

ERIS Lifesciences Ltd has a market capitalization of approximately 18,805.75. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

ERIS Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 18,805.75 Cr, ERIS Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

ERIS Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 28.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The call is scheduled for Wednesday, July 29, 2026 at 4:30 PM IST.

Eris Lifesciences declared an interim dividend of ₹7.21 per share (721%) for FY26-27.

Operating revenue rose 7% YoY to INR 757 crore, EBITDA increased 8% to INR 274 crore, and net profit rose to INR 279 crore, aided by a deferred tax gain.

Consolidated net profit was ₹281.6 crore and revenue from operations rose 7.3% year-on-year to ₹756.5 crore (also cited as ₹756.56 crore).